KFDA approves arthritis treatment Orencia

The Korea Food and Drug Administration said on Mach 29 it has granted final approval to Bristol-Myers Squibb's (BMS) Orencia — a potential blockbuster arthritis treatment, according to BMS Korea.

Administered intravenously, Orencia is a first-in-class selective co-stimulation modulator designed to inhibit the action of T-cells, which manage the autoimmune response that leads to joint inflamm...